Aptevo Therapeutics (APVO) Common Equity (2015 - 2026)
Aptevo Therapeutics (APVO) posted Common Equity of $11.6 million for Q1 2026, down 33.19% sequentially from $17.4 million in Q4 2025, and up 888.32% YoY from $1.2 million in Q1 2025.
Aptevo Therapeutics (APVO) Common Equity (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Common Equity for 12 years, with the latest figure at $11.6 million in Q1 2026.
- Quarterly Common Equity rose 888.32% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 888.32% YoY) and the FY2025 annual result came in at $17.4 million, up 265.53% from the prior year.
- Common Equity retreated to $11.6 million in Q1 2026 per APVO's latest filing, from $17.4 million in the prior quarter.
- Over five years, Common Equity peaked at $23.3 million in Q1 2023 and troughed at -$5.9 million in Q1 2022.
- A 5-year average of $11.1 million and a median of $12.2 million in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 1378.12% in 2022, down 156.02% in 2022.
- Over 5 years, Common Equity stood at $18.0 million in 2022, then slumped by 32.01% to $12.2 million in 2023, then plunged by 61.09% to $4.8 million in 2024, then surged by 265.53% to $17.4 million in 2025, then sank by 33.19% to $11.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $11.6 million, $17.4 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.79 Bn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | 6.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.04 Mn |
| Mar 31, 2026 | 11.61 Mn |
| Dec 31, 2025 | 17.38 Mn |
| Sep 30, 2025 | 17.39 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Dec 31, 2023 | 12.22 Mn |
| Sep 30, 2023 | 14.72 Mn |
| Jun 30, 2023 | 16.25 Mn |
| Mar 31, 2023 | 23.26 Mn |
| Dec 31, 2022 | 17.97 Mn |
| Sep 30, 2022 | 15.76 Mn |
| Jun 30, 2022 | 23.05 Mn |
| Mar 31, 2022 | -5.88 Mn |
| Dec 31, 2021 | 1.22 Mn |
| Sep 30, 2021 | 7.29 Mn |